Trials / Completed
CompletedNCT00076544
Ziconotide Effectiveness and Safety Trial in Patients With Chronic Severe Pain
An Open-Label, Long-Term, Multi-Center, Intrathecal Ziconotide (PRIALT) Effectiveness and Safety Trial (ZEST) in Patients With Chronic Severe Pain
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 300 (planned)
- Sponsor
- Elan Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this open-label study is to give chronic severe pain patients with existing intrathecal pump systems access to ziconotide.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ziconotide |
Timeline
- Start date
- 2004-02-01
- Primary completion
- 2005-03-01
- First posted
- 2004-02-04
- Last updated
- 2015-12-14
Locations
65 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00076544. Inclusion in this directory is not an endorsement.